Dow 30

9-Comparable Valuation Sheet

The main competitors for Pfizer are Johnson & Johnson, Merck Inc. and Eli Lilly. Pfizer’s 2012 revenues of $58.99 billion were second only to Johnson & Johnson’s $69.99 billion. Though it has such high revenues the company is valued at a forward price to earnings multiple of 13.59x, which is lowest within its competition. Pfizer did have the highest gross margin compared to others showing that the company’s cost management is improving and has the potential to further improve given its restructuring plans. This will also lead the company to be valuated at a higher multiple and increase its stock price.

comments powered by Disqus